Virginia · 2025 Regular Session · Bill
SB 592: Preferred Drug List/Common Core Formulary; approval of a nonpreferred drug.
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
SB 592 is a bill introduced in the Virginia Senate on January 10, 2024. According to its official title, it concerns: Preferred Drug List/Common Core Formulary; approval of a nonpreferred drug. Primary sponsor: Saddam Salim (Democratic). Most recent recorded action (November 19, 2024): Left in Education and Health.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.
Department of Medical Assistance Services; Preferred Drug List/Common Core Formulary; approval of a nonpreferred drug. Directs the Department of Medical Assistance Services to eliminate the requirement that a patient try and fail a drug from the Preferred Drug List/Common Core Formulary in the six months immediately prior to approval of a nonpreferred drug when such patient has previously tried the drug from the Preferred Drug List/Common Core Formulary and experienced harmful side effects.
Sponsors
Sponsors by party (alphabetical): Democratic 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Saddam Salim | Primary sponsor | Democratic | Senate | 37 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- Left in Education and Health
- Continued to 2025 in Education and Health (15-Y 0-N)
- Assigned Education and Health Sub: Health
- Impact statement from DPB (SB592)
- Referred to Committee on Education and Health
- Prefiled and ordered printed; offered 01/10/24 24103030D